Telix Pharmaceuticals (TLPPF) Cash & Equivalents (2023 - 2026)

Telix Pharmaceuticals (TLPPF) has reported Cash & Equivalents for 4 consecutive years, with $251.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash & Equivalents changed N/A year-over-year to $251.9 million in Q2 2026; TTM through Jun 2026 was $251.9 million, a N/A change from a year earlier, with the FY2025 full-year figure at $141.9 million, down 67.76% from the prior year.
• Cash & Equivalents was $251.9 million for Q2 2026 at Telix Pharmaceuticals, up from $141.9 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $464.5 million in Q4 2024 and troughed at $80.2 million in Q4 2023.
• A 4-year average of $234.6 million and a median of $196.9 million in 2025 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents soared 479.03% in 2024 and slumped 69.46% in 2025, its largest moves.
• Over 4 years, Cash & Equivalents stood at $80.2 million in 2023, then soared by 479.03% to $464.5 million in 2024, then tumbled by 69.46% to $141.9 million in 2025, then soared by 77.57% to $251.9 million in 2026.
• The last three Cash & Equivalents figures came in at $251.9 million (Q2 2026), $141.9 million (Q4 2025), and $464.5 million (Q4 2024), per Business Quant data.